2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. Show more

Location: 60 Binney Street, Cambridge, MA, 02142, United States | Website: https://www.2seventybio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

266.1M

52 Wk Range

$2.29 - $5.30

Previous Close

$5.00

Open

$5.00

Volume

N/A

Day Range

$5.00 - $5.00

Enterprise Value

335.5M

Cash

170.4M

Avg Qtr Burn

-13.52M

Insider Ownership

6.44%

Institutional Own.

82.40%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.